Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes.
4 reports, 2 independent
Updated Aug 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Roche was appointed as the new CFO of Iovance Biotherapeutics.Sub-event
Iovance Biotherapeutics revenue gains from Amtagvi, market underperformance, and leadership changes.1 source
- CFO resigned and final clinical trial results were published for lifileucel.
Keep exploring
The entities involved
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.
-
lifileucel
experimental autologous cell therapy for metastatic melanoma
Nothing else this week.
Coverage
Newest first; wire copies grouped- Simply Wall St.Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million Iovance Biotherapeutics announced revenue gains despite losses in its Q2 2025 results. On August 7, the company reiterated i
- Motley FoolWhy Iovance Biotherapeutics Stock Plummeted Today Investors were hardly pleased by the company's double miss on second-quarter results. At least its revenue guidance was in line with expectations. 10
- Motley FoolIs Iovance Biotherapeutics Stock Due for a Big Rally? Iovance's stock has been surging, and trading volumes have been up recently, despite no significant news. The company's approved cellular therapy
- Unknown outlet